+86 400-682-2521 | order.cn@acrobiosystems.com 注册
登录 | 注册    关注公众号 |  
微信公众号
ACRO百普赛斯_logo Recombinant Proteins iso9001 ISO13485 CNAS
热门搜索：TL1A Hot|GMP细胞因子Hot|FcRn Binding Kit (TR-FRET)New|ADC定点偶联试剂盒
ABCDEFGHIJKLMNOPQRSTUVWXYZ0-9
搜索
 > 【Angiopoietin-like Protein 2】

Angiopoietin-like Protein 2产品咨询

* 此表格只用于收集产品需求咨询，所有信息将严格保密。
*
*
*
*
*
*
抗体药
 
细胞治疗
 
基因治疗
 
诊断
 
疫苗
 
化药
 
蛋白及多肽药物
 
神经科学
 
XDC
 
其他
 
ACRO质量管理体系
 
评论(0)
 

Angiopoietin-like Protein 2 分子别名

Angiopoietin-like Protein 2,ANGPTL2,ARP2,Angiopoietin-related protein 2

Angiopoietin-like Protein 2 分子背景

Angiopoietin-like Protein 2 (ANGPTL2), also known as ARP2 is a secreted glycoprotein that contains a N-terminal coiled coil domain and a C-terminal fibrinogen like domain. ANGPTL2 has both pro and anti-angiogenic functions. It serves as tumor suppressor in ovarian cancer, and also promote metastasis in various cancer types, making it potential biomarker for tumor progression. ANGPTL2 also function as growth factor to enhance the survival of hematopoietic progenitors, mediated by its coiled coil domain. Receptor of ANGPTL2 is recently identified as LILRB2, and both the coiled coil domain and fibrinogen like domain are required for optimal binding.

Angiopoietin-like Protein 2 前沿进展

A novel photosensitive nanoprobe combined with CRISPR/Cas12a for dual signal amplification detection of ANGPTL2
Chen, Zhao, Yu et al
Talanta (2025) 292, 128010
Abstract: The detection of specific protein biomarkers holds significant potential for the early diagnosis of colorectal cancer (CRC). However, the accurate quantification of low-abundance proteins in serum presents a major challenge due to factors such as limited sensitivity and the complexity of the required methodologies. In this work, we established a universal CRISPR/Cas biosensing platform by integrating novel photosensitive nanoprobes (DA/PL@Cu NPs) and CRISPR/Cas12 system (DPC-Cas) for the highly sensitive, specific and user-friendly detection of angiopoietin-like protein 2 (ANGPTL2). The DA/PL@Cu NPs serve as a critical component in the transduction of protein recognition information into nucleic acid amplification events to produce Cas12a activators. The DPC-Cas biosensor integrates DA/PL@Cu NPs-assisted amplification with Cas12a self-amplification, enabling ultrasensitive detection of ANGPTL2 at concentrations as low as 20.00 pg/mL. The proposed DPC-Cas biosensor successfully detected ANGPTL2 in serum, demonstrating significant potential for the early diagnosis of CRC.Copyright © 2025 Elsevier B.V. All rights reserved.
Colony-stimulating factor 3 and its receptor promote leukocyte immunoglobulin-like receptor B2 expression and ligands in gastric cancer
Wang, Wu, Zhang et al
World J Gastrointest Oncol (2025) 17 (2), 97858
Abstract: Colony-stimulating factor 3 (CSF3) and its receptor (CSF3R) are known to promote gastric cancer (GC) growth and metastasis. However, their effects on the immune microenvironment remain unclear. Our analysis indicated a potential link between CSF3R expression and the immunosuppressive receptor leukocyte immunoglobulin-like receptor B2 (LILRB2) in GC. We hypothesized that CSF3/CSF3R may regulate LILRB2 and its ligands, angiopoietin-like protein 2 (ANGPTL2) and human leukocyte antigen-G (HLA-G), contributing to immunosuppression.To investigate the relationship between CSF3/CSF3R and LILRB2, as well as its ligands ANGPTL2 and HLA-G, in GC.Transcriptome sequencing data from The Cancer Genome Atlas were analyzed, stratifying patients by CSF3R expression. Differentially expressed genes and immune checkpoints were evaluated. Immunohistochemistry (IHC) was performed on GC tissues. Correlation analyses of CSF3R, LILRB2, ANGPTL2, and HLA-G were conducted using The Cancer Genome Atlas data and IHC results. GC cells were treated with CSF3, and expression levels of LILRB2, ANGPTL2, and HLA-G were measured by quantitative reverse transcriptase-polymerase chain reaction and western blotting.Among 122 upregulated genes in high CSF3R expression groups, LILRB2 showed the most significant increase. IHC results indicated high expression of LILRB2 (63.0%), ANGPTL2 (56.5%), and HLA-G (73.9%) in GC tissues. Strong positive correlations existed between CSF3R and LILRB2, ANGPTL2, and HLA-G mRNA levels (P < 0.001). IHC confirmed positive correlations between CSF3R and LILRB2 (P < 0.001), and HLA-G (P = 0.010), but not ANGPTL2 (P > 0.05). CSF3 increased LILRB2, ANGPTL2, and HLA-G expression in GC cells. Heterogeneous nuclear ribonucleoprotein H1 modulation significantly altered their expression, impacting CSF3's regulatory effects.The CSF3/CSF3R pathway may contribute to immunosuppression in GC by upregulating LILRB2 and its ligands, with heterogeneous nuclear ribonucleoprotein H1 playing a regulatory role.©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Prognostic value of serum angiopoietin-like protein 2 in patients with acute coronary syndrome
Zuo, Zhang, Xie
BMC Cardiovasc Disord (2024) 24 (1), 709
Abstract: Angiopoietin-like protein 2 (Angptl2) is a cytokine that is released to stimulate inflammation and accelerate atherogenesis. Our study sought to assess the predictive significance of serum Angptl2 in individuals diagnosed with acute coronary syndrome (ACS) and determine whether it can enhance prognostic performance beyond the GRACE risk score.We recruited a total of 1060 patients with ACS in a consecutive manner. The levels of Angptl2 in serum were analyzed at baseline. The subjects were then followed up for 12 months to monitor the occurrence of major adverse cardiovascular events (MACE).The level of serum Angptl2 showed a positive correlation with the GRACE score (r = 0.54, p < 0.001). Survival analysis revealed that increased levels of serum Angptl2 were associated with higher occurrence of the composite of MACE (log-rank p < 0.001) and its specific components (log-rank p = 0.011 for all-cause death, p = 0.007 for non-fatal myocardial infarction and p < 0.001 for revascularization respectively). Throughout the follow-up period, 163 instances (15.4%) of endpoint events were documented. In terms of MACE, both serum Angptl2 levels (HR: 1.178, 95% CI: 1.058-1.313, p = 0.003) and the GRACE risk score (HR: 1.181, 95% CI: 1.007-1.385, p = 0.041) emerged as significant predictors following Cox multivariate adjustment. Additionally, the addition of serum Angptl2 to the GRACE score improved the predictive capacity for prognosis [increase in area under the receiveroperating characteristic curve (AUC) from 0.740 to 0.794, p = 0.020; net reclassification improvement (NRI) = 0.401, p = 0.001; integrated discrimination improvement (IDI) = 0.022, p = 0.008].Serum Angptl2 might be a useful prognostic biomarker and combining serum Angptl2 with the GRACE score increased the efficacy of prognosis prediction in ACS patients.Not applicable.© 2024. The Author(s).
Showing 1-3 of 258 papers.
Powered by BizGenius

扫一扫关注微信公众号获取ACRO最新资讯

ACROBiosystems百普赛斯生物科技股份有限公司

全国：+86 400-682-2521

北京：010-53681107

上海：021-50850665

海外：+1 800-810-0816

邮箱：（产品订购）order.cn@acrobiosystems.com

邮箱：（技术支持）tech.cn@acrobiosystems.com

邮箱：（廉洁合规）lianjie@acrobiosystems.com

地址：北京经济技术开发区宏达北路8号5号楼4层

新闻订阅

订阅

在线留言

发送
隐私政策 | 法律法规 | 网站地图 | 加入我们
©2017 ACROBiosystems中国 京公网安备 11030102010599号 京ICP备16032159号-1

消息提示

请输入您的联系方式,再点击提交！

确定